Lantern Pharma Inc.
Close on Oct 19, 2026
- Market cap
- $7.97M
- P/E (TTM)
- –
- Dividend yield
- –
About Lantern Pharma
Pharmaceutical Preparations, SIC 2834
Lantern Pharma Inc. is an artificial intelligence-focused biotechnology company dedicated to developing targeted cancer therapies. The company operates a proprietary machine learning and big data analytics platform called RADR to identify biologically relevant genomic signatures, discover drug candidates, and match therapies with specific cancer patient populations likely to respond. Its clinical-stage portfolio focuses on small molecule oncology candidates, including lead programs LP-300, LP-184, and LP-284, addressing solid tumors and blood cancers. Additionally, the company advances an antibody-drug conjugate development program, an AI platform named withZeta.ai for rare cancer research, and central nervous system oncology candidates through its subsidiary, Starlight Therapeutics.
The company maintains its principal executive offices in Dallas, Texas. Its operations incorporate clinical programs evaluating therapies across several indications, such as triple-negative breast cancer and non-small cell lung cancer. The text does not provide details on foreign facilities, physical operating locations, or store counts.
Summary of the business section of Lantern Pharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lantern Pharma Inc.
- Headquarters
- Dallas, TX
- Address
- 1920 Mckinney Avenue, 7th Floor 75201
- Phone
- (972) 277-1136
- Website
- withzeta.ai
- Employees
- 16, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Texas
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- LTRN
- Exchange
- Nasdaq
- IPO date
- Jun 12, 2020
- Shares outstanding
- 13M, Aug 10, 2026
- Public float
- $33.94M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1763950
- CUSIP
- 51654W101
- ISIN
- US51654W1018
- EIN
- 46-3973463
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Panna Sharma | President & CEO, Director | – |
| Kishor G. Bhatia | Chief Scientific Officer | – |
| David R. Margrave | Chief Financial Officer | – |
| Lee Troy Schalop | Director | 48,544 |
| D. Jeffrey Keyser | Director | 94,303 |
| David S. Silberstein | Director | 1,044,000 |
| Vijay Chandru | Director | – |
| Maria-Luisa Maccecchini | Director | – |
Employees
Headcount reported in annual reports
“of the date of this report, we employ a total of 16 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Oct 1, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jun 12, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 8, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jan 14, 2019 | Name change | Name changed from Lantern Pharma to Lantern Pharma Inc. |